# Lifecore Biomedical, Inc. \\de\\: overview LFCR · Nasdaq · CIK 1005286 · [Healthcare](/sectors/healthcare.md) · fiscal year ends May 25 Pages: [Overview](/companies/lfcr.md) · [Financials](/companies/lfcr/financials.md) · [Filings](/companies/lfcr/filings.md) · [Insiders](/companies/lfcr/insiders.md) Latest reported revenue: [$34.2m](/filings/0001005286-26-000033.md) for Q2 FY2027, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001005286-26-000033). ## Last eight quarters | Line item | Unit | Q4 FY2024 (2024-05-26) | Q1 FY2025 (2024-08-25) | Q2 FY2025 (2024-11-24) | Q3 FY2025 (2025-02-23) | Q4 FY2025 (2025-05-25) | Q1 FY2026 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2027 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [37.9 d](/filings/0001005286-26-000009.md) | [24.7](/filings/0001005286-25-000148.md) | [32.6](/filings/0001005286-25-000012.md) | [35.2](/filings/0001005286-26-000020.md) | [36.4](/filings/0001005286-26-000033.md) | [31.1](/filings/0001005286-25-000148.md) | [23.2](/filings/0001005286-26-000020.md) | [34.2](/filings/0001005286-26-000033.md) | | Gross margin | % | [45.6% d](/filings/0001005286-26-000009.md) | [21.8%](/filings/0001005286-25-000148.md) | [34.0%](/filings/0001005286-25-000012.md) | [28.0%](/filings/0001005286-26-000020.md) | [38.4%](/filings/0001005286-26-000033.md) | [25.0%](/filings/0001005286-25-000148.md) | [19.2%](/filings/0001005286-26-000020.md) | [35.3%](/filings/0001005286-26-000033.md) | | Operating margin | % | [5.7% d](/filings/0001005286-26-000009.md) | [(46.9%)](/filings/0001005286-25-000148.md) | [(6.0%)](/filings/0001005286-25-000012.md) | [(25.7%)](/filings/0001005286-26-000020.md) | [14.6%](/filings/0001005286-26-000033.md) | [(9.9%)](/filings/0001005286-25-000148.md) | [(20.1%)](/filings/0001005286-26-000020.md) | [7.5%](/filings/0001005286-26-000033.md) | | Net margin | % | [(18.7%) d](/filings/0001005286-26-000009.md) | [(65.7%)](/filings/0001005286-25-000148.md) | [(20.2%)](/filings/0001005286-25-000012.md) | [(42.0%)](/filings/0001005286-26-000020.md) | [(3.1%)](/filings/0001005286-26-000033.md) | [(32.1%)](/filings/0001005286-25-000148.md) | [(64.6%)](/filings/0001005286-26-000020.md) | [(18.0%)](/filings/0001005286-26-000033.md) | | Diluted EPS | $ per share | not reported | [(0.53)](/filings/0001005286-25-000148.md) | [(0.25)](/filings/0001005286-25-000012.md) | [(0.42)](/filings/0001005286-26-000020.md) | [(0.06)](/filings/0001005286-26-000033.md) | [(0.29)](/filings/0001005286-25-000148.md) | [(0.43)](/filings/0001005286-26-000020.md) | [(0.19)](/filings/0001005286-26-000033.md) | | Free cash flow | $m | [6.0 d](/filings/0001005286-26-000009.md) | [(4.0)](/filings/0001005286-25-000148.md) | [(8.6) d](/filings/0001005286-25-000012.md) | [(4.3)](/filings/0001005286-26-000020.md) | [3.3 d](/filings/0001005286-26-000009.md) | [0.0](/filings/0001005286-25-000148.md) | [3.6](/filings/0001005286-26-000020.md) | [(2.7) d](/filings/0001005286-26-000033.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-05-30) | FY2022 (2022-05-29) | FY2023 (2023-05-28) | FY2024 (2024-05-26) | FY2025 (2025-05-25) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [101](/filings/0001005286-24-000030.md) | [111](/filings/0001005286-24-000124.md) | [103](/filings/0001005286-24-000124.md) | [128](/filings/0001005286-26-000009.md) | [129](/filings/0001005286-26-000009.md) | | Gross margin | % | [38.6%](/filings/0001005286-24-000030.md) | [35.1%](/filings/0001005286-24-000124.md) | [27.1%](/filings/0001005286-24-000124.md) | [32.6%](/filings/0001005286-26-000009.md) | [31.3%](/filings/0001005286-26-000009.md) | | Operating margin | % | [(8.7%)](/filings/0001005286-24-000030.md) | [(10.6%)](/filings/0001005286-24-000124.md) | [(21.1%)](/filings/0001005286-24-000124.md) | [(6.9%)](/filings/0001005286-26-000009.md) | [(13.4%)](/filings/0001005286-26-000009.md) | | Net margin | % | [(32.0%)](/filings/0001005286-24-000030.md) | [(104.9%)](/filings/0001005286-24-000124.md) | [(96.4%)](/filings/0001005286-24-000124.md) | [9.4%](/filings/0001005286-26-000009.md) | [(30.0%)](/filings/0001005286-26-000009.md) | | Diluted EPS | $ per share | [(1.10)](/filings/0001005286-24-000030.md) | [(3.97)](/filings/0001005286-24-000124.md) | [(3.32)](/filings/0001005286-24-000124.md) | [0.33](/filings/0001005286-26-000009.md) | [(1.27)](/filings/0001005286-26-000009.md) | | Free cash flow | $m | [(2.8)](/filings/0001005286-24-000030.md) | [(48.8)](/filings/0001005286-24-000124.md) | not reported | [(18.1)](/filings/0001005286-26-000009.md) | [(13.6)](/filings/0001005286-26-000009.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/lfcr/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [WYNNEFIELD CAPITAL INC](/funds/1251567.md) | 2026-06-30 | $24.7m | 4,703,216 | | Unchanged | | [Legion Partners Asset Management, LLC](/funds/1560207.md) | 2026-06-30 | $23.4m | 4,461,823 | | Unchanged | | [Greenhaven Road Investment Management, L.P.](/funds/1741129.md) | 2026-06-30 | $16.8m | 3,190,769 | | Reduced −346,804 | | [325 CAPITAL LLC](/funds/1873893.md) | 2026-06-30 | $15.2m | 2,895,881 | | Added +733,415 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $10.6m | 2,013,093 | | Added +135,788 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $6.8m | 1,288,621 | | Reduced −1,515 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $4.5m | 855,500 | | Added +40,393 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $4.0m | 769,360 | | Added +4,626 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $3.5m | 668,031 | | Added +26,025 | | [Quinn Opportunity Partners LLC](/funds/1633275.md) | 2026-06-30 | $2.4m | 453,495 | | Unchanged | ## Recent filings [All 1,191 filings](/companies/lfcr/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-20 | 16:30 ET | [8-K](/filings/0001005286-26-000040.md) | 8.01 Other events | 0001005286-26-000040 | | 2026-09-29 | 16:15 ET | [SCHEDULE 13D/A](/filings/0001104659-26-111939.md) | Ownership report, active investor, amended | 0001104659-26-111939 | | 2026-09-29 | 16:12 ET | [8-K](/filings/0001005286-26-000036.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001005286-26-000036 | | 2026-09-28 | 17:41 ET | [SCHEDULE 13D/A](/filings/0000921895-26-002661.md) | Ownership report, active investor, amended | 0000921895-26-002661 | | 2026-09-28 | 08:53 ET | [8-K](/filings/0001140361-26-037767.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-037767 | | 2026-08-05 | 07:20 ET | [10-Q](/filings/0001005286-26-000033.md) | Quarterly report, period 2026-06-30 | 0001005286-26-000033 | | 2026-08-05 | 07:17 ET | [8-K](/filings/0001005286-26-000032.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001005286-26-000032 | | 2026-07-02 | 17:36 ET | [SCHEDULE 13D/A](/filings/0000921895-26-001747.md) | Ownership report, active investor, amended | 0000921895-26-001747 | | 2026-07-02 | 17:17 ET | [8-K](/filings/0001005286-26-000026.md) | 7.01 Regulation FD disclosure | 0001005286-26-000026 | | 2026-07-02 | 17:15 ET | [SCHEDULE 13D/A](/filings/0001193125-26-294951.md) | Ownership report, active investor, amended | 0001193125-26-294951 | ## Latest annual report [Form 10-K for the fiscal year ended May 25, 2025](/filings/0001005286-25-000108.md), filed Aug 7, 2025. ## Forecast league Q3 FY2027, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/426dd96c-29a0-4649-a6fa-1d7cf9d98d91) ## About the filer - CIK: 1005286 - Tickers: LFCR - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 17:35 ET. No prices; not investment advice.